Pseudoephedrine

Evidence Level: L5

Predicted Indications: 2

Pseudoephedrine

Pharmacist Assessment Report

Pseudoephedrine: From Allergic Rhinitis and Common Cold to Nasal Cavity Disease

One-Sentence Summary

Pseudoephedrine is a decongestant originally used for allergic rhinitis, vasomotor rhinitis, the common cold, pharyngitis and related upper-airway conditions. The TxGNN model predicts it may be effective for nasal cavity disease, but there are no registered clinical trials and only 7 publications (one review, one clinical pharmacology study and five animal-model studies). This prediction largely overlaps with the drug’s existing uses, so it is better seen as an extension of current use than as true repurposing.

Quick Overview

Item	Content
Original Indication	Allergic rhinitis, vasomotor rhinitis, pharyngitis, common cold and related conditions (the licence records contain no approved indication text)
Predicted New Indication	Nasal cavity disease
TxGNN Prediction Score	0.9975
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled data. Based on known pharmacology, pseudoephedrine is an indirect sympathomimetic with alpha-adrenergic agonist activity. It constricts blood vessels in the nasal mucosa, which reduces swelling and congestion.

Nasal cavity disease is a broad category that includes the rhinitis conditions already among pseudoephedrine’s original indications. The mechanism (reducing mucosal swelling) therefore applies directly. The high TxGNN score is likely driven by this close similarity to approved rhinitis uses.

Two other predictions were also generated but are not supported. Acute laryngopharyngitis has no trials or literature, and pseudoephedrine has no known effect on laryngeal inflammation or infection. Allergic urticaria has no mechanistic rationale: pseudoephedrine has no antihistamine activity, and all retrieved papers concern antihistamines, not pseudoephedrine.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22794679	2012	Review	Allergy Asthma Proc	Overview of nonallergic rhinitis: inflammatory and noninflammatory causes presenting with congestion, rhinorrhea, sneezing and postnasal discharge
11345158	2001	Clinical pharmacology study	Am J Rhinol	Compared oral and topical decongestant effects of phenylpropanolamine and d-pseudoephedrine on nasal cavity dimensions using acoustic rhinometry
19769798	2009	Animal model (cat)	Am J Rhinol Allergy	Loratadine and montelukast combination produced decongestion; d-pseudoephedrine was also studied with and without desloratadine
12962193	2003	Animal model (dog)	Am J Rhinol	Model of allergic nasal congestion in ragweed-sensitized dogs
12387934	2002	Animal model (dog)	J Pharmacol Toxicol Methods	Pharmacological characterization of a chronic dog model of nasal congestion
11895194	2002	Animal model (dog)	Am J Rhinol	Acoustic rhinometry as a large-animal model for nasal congestion studies
24492651	2014	Animal model	J Pharmacol Exp Ther	Selective α2c-adrenergic agonists evaluated in animal models of nasal congestion

India Market Information

Twenty single-ingredient licences are valid and none are cancelled. The main ones are listed below; the licence records contain no approved indication text.

Authorization Number	Product Name	Dosage Form	Approved Indication
51888	Cofsyryl Syrup	Syrup, 60 ml bottle	Not stated in records
137963	Megatuss D Syrup	Syrup, 100 ml bottle	Not stated in records
189886	Ricold Tablet	Tablet, strip of 10	Not stated in records
241783	Wytuss Syrup	Syrup, 100 ml bottle	Not stated in records
70055	Drykof 15 mg/5 mg/2.5 mg Syrup	Syrup, 100 ml bottle	Not stated in records

Safety Considerations

Contraindications flagged in the knowledge graph (not label text): hypertension and other hypertensive disorders, coronary artery disease, congestive heart failure, stroke and cerebrovascular disorders, diabetes mellitus and diabetic ketoacidosis, hypothyroidism, liver and kidney disease or failure, epilepsy, COPD, peptic ulcer disease, benign prostatic hyperplasia, and others.
Drug Interactions: 150 interactions were identified. Those listed are mostly Moderate-level, with antidiabetic agents prominent: acarbose, glimepiride, glipizide, glyburide, chlorpropamide, canagliflozin, dapagliflozin, empagliflozin, exenatide, dulaglutide and several insulins. Diethylpropion is also listed as Moderate, and ascorbic acid as Minor.

Package insert warnings and contraindications were not available in the compiled data. Please refer to the package insert for label safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Nasal cavity disease overlaps substantially with pseudoephedrine’s existing rhinitis and nasal congestion uses, and the drug is widely marketed in India, so the prediction is plausible. However, there are no registered trials and the supporting literature is mostly animal-model or non-pseudoephedrine work, so this is an extension of current use rather than a newly validated indication. The other two predictions (acute laryngopharyngitis, allergic urticaria) should stay on Hold.

To proceed, the following is needed:

Package insert warnings and contraindications from the India Pharma sources (this is a blocking gap for safety screening)
Detailed mechanism of action data from DrugBank
A clearer definition of which nasal cavity conditions are targeted beyond current labeled rhinitis uses
Clinical studies in the specific conditions of interest
A cardiovascular, metabolic and interaction risk-management plan, given the many knowledge-graph contraindications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.